A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRSD107 in Healthy Chinese Subjects

Inclusion Criteria: * Males or females, of any race, between 18 and 65 years of age, inclusive. * Body mass index between 18.0 and 32.0 kg/square meter, inclusive. * In good health, determined by no clinically significant findings from medical history, physical examination, clinical laboratory evaluations, 12 lead ECG, and vital signs measurements, at screening and check in, as assessed by the investigator (or designee). * Activated partial thromboplastin time and prothrombin time within the normal reference range. * Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as pre-defined in the protocol. * Able to comprehend and willing to sign an ICF and to abide by the study restrictions. Exclusion Criteria: * Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee). * History or evidence of any abnormal bleeding or coagulation disorder; or evidence of coagulopathy, prolonged or unexplained, clinically significant bleeding, or frequent unexplained bruising or thrombus formation; or a history of spontaneous bleeding. * Evidence of an active or suspected cancer, or a history of malignancy, within 5 years prior to screening. Nonmelanoma skin cancer, curatively treated localized prostate cancer…